参芪扶正注射液辅助TACE治疗原发性肝癌的Meta分析

发布时间：2018-03-13 15:51

本文选题：参芪扶正注射液　切入点：原发性肝癌　出处：《中国药房》2017年27期 　论文类型：期刊论文

【摘要】：目的:系统评价参芪扶正注射液辅助肝动脉栓塞化疗(TACE)用于原发性肝癌的有效性和安全性,为临床提供循证参考。方法:计算机检索相关期刊论文、万方数据库、中文科技期刊数据库和Pub Med,纳入参芪扶正注射液联合TACE(试验组)对比单纯TACE(对照组)治疗原发性肝癌的随机对照试验(RCT),提取资料并应用改良Jadad量表评价纳入研究质量后,采用Stata 12.0统计软件进行Meta分析。结果:共纳入8项RCT,合计527例患者。Meta分析结果显示,两组患者治疗有效率[RR=1.19,95%CI(0.97,1.46),P=0.091]、临床受益率[RR=1.16,95%CI(0.90,1.48),P=0.251]比较,差异均无统计学意义;试验组患者生存质量改善率显著高于对照组[RR=2.26,95%CI(1.64,3.10),P=0.001],中度以上发热发生率[RR=0.74,95%CI(0.63,0.88),P=0.001]、胃肠道反应发生率[RR=0.52,95%CI(0.32,0.85),P=0.010]和白细胞减少发生率[RR=0.75,95%CI(0.62,0.92),P=0.005]均显著低于对照组,差异均有统计学意义。结论:参芪扶正注射液用于原发性肝癌TACE的辅助治疗不能提高患者的临床疗效,但可提高患者生存质量,降低发热、胃肠道反应和骨髓抑制的发生率。
[Abstract]:Objective: to evaluate the efficacy and safety of Shenqi Fuzheng injection assisted hepatic artery chemoembolization (TACEE) in the treatment of primary liver cancer and to provide evidence based reference for clinical application. Methods: the full text database of Chinese Journal and the database of Wanfang were searched by computer. Chinese sci-tech journal database and Pub Med. were included in the randomized controlled trial of Shenqi Fuzheng injection combined with TACE (trial group) in the treatment of primary liver cancer compared with the control group. The data were extracted and the modified Jadad scale was used to evaluate the quality of the study. Stata 12.0 statistical software was used to analyze Meta. Results: totally 527 patients. Meta-analysis results showed that the effective rate of the two groups was 0.971.46%, and the clinical benefit rate [RRN 1.1695%] was 0.901.48% P0.251, there was no significant difference between the two groups. The improvement rate of quality of life (QOL) in the trial group was significantly higher than that in the control group [RRX 2.2695 CIQ 1.64 3.10P0.001], the incidence of fever above moderate level [RRRO0.7495CI0.630.88P0.001], the incidence of gastrointestinal reaction [RRN0.5295CI0.320.85 P0.010] and the incidence of leukocytopenia [RRN0.7595CI0.62C0.62P0.005] were significantly lower than those in the control group. Conclusion: the adjuvant treatment of Shenqi Fuzheng injection for primary liver cancer TACE can not improve the clinical efficacy, but can improve the quality of life of patients, reduce the incidence of fever, gastrointestinal reaction and bone marrow suppression.
【作者单位】：贵州省人民医院;
【基金】：国家自然科学基金资助项目(No.31360220) 贵州省科学技术基金资助项目(No.黔科合丁字[2012]2241号)
【分类号】：R735.7

【相似文献】